An invasive strategy vs. optimal medical therapy alone after a non-ST-elevation myocardial infarction (NSTEMI) in older ...

No impact was seen on mortality between the invasive and medical arms, but other endpoints may mean more to patients.

Using optimal coherence tomography (OCT) to guide stent implantation during percutaneous coronary intervention (PCI) in ...

An international team of researchers, led by one of Indian origin, has demonstrated that a drug used to treat kidney diseases ...

Since the 1960s, cardiologists have adopted several binary classification systems for acute myocardial infarction (MI) that ...

Deepak Bhatt, MD, Mount Sinai Heart, highlights the kidney-specific outcomes of the pivotal EMPACT-MI clinical trial in an interview at the 2024 European Society of Cardiology Congress.

The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a ...

The cardiovascular safety of interrupting beta-blocker could not be shown in comparison to continuation in patients with a history of myocardial infarction (MI) and there was no benefit to the ...

In a large meta-analysis, complete revascularisation reduced cardiovascular events compared with culprit-only revascularisation in older patients ...

Quickly cutting non-HDL cholesterol after MI lowers the risk of MACE compared with stepwise use of lipid-lowering therapy.

During a press conference, Silvain recommended not stopping chronic beta-blocker treatment -- which may be considered ...

The appropriate duration of beta-blocker treatment after a heart attack (a myocardial infarction [MI]) is unknown in patients who do not need to take beta-blockers for another reason. In the ABYSS ...